Zihaad Wells to Return to True Religion Apparel as Creative Director
True Religion Apparel, Inc. announced today that Zihaad Wells has been appointed its new Creative Director, effective immediately. Mr. Wells was previously Vice President of Design for True Religion Apparel from 2006 to 2017 and most recently Vice President of Design and Creative at AG Jeans. He will be responsible for product design, marketing and driving the creative direction of the brand. Mr. Wells reports to Michael Buckley, the Chief Executive Officer.
Zihaad Wells has a deep understanding of the branded denim industry across brand, product, wholesale, retail and ecommerce with over 20 years’ experience. Wells started his career for Levi’s Europe, where he worked on Levi’s Red and Levi’s Vintage collections, before coming to True Religion Apparel in 2006.
Michael Buckley, Chief Executive Officer, stated, “We are extremely excited and proud to welcome Zihaad Wells back to True Religion Apparel. Zihaad is one of the leading denim and sportswear creatives in the industry.”
Commenting on his appointment, Mr. Wells added, “I am extremely excited to return to True Religion as its Creative Director, it feels like coming home. I look forward to working with Michael and the team to get back to the DNA of what made True Religion an amazing brand, which was the perfect balance of heritage and modernity rooted in iconic Jeanswear.”
About True Religion Apparel, Inc.
In 2002, True Religion emerged onto the Los Angeles denim scene by blowing up the construction of the classic five-pocket jean. With its five-needle thread at two-stitch-per-inch process, the True Religion Super T stitch was instantly recognized for style that was unlike any other denim brand in the world. True Religion speaks to the uniqueness found in all of us. The brand is worn by athletes, musicians, and artists globally to express their individual style. Delivering an exclusive assortment of iconic styles, True Religion Brand Jeans focuses on producing high quality premium denim and sportswear for men’s, women’s and kids.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005232/en/
Contact information
For True Religion:
Kate Kaminsky
kate@michelemariepr.com
646.863.3923
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 09:00:00 EET | Press release
Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leading cause of business loss, the need for advanced security measures continues to grow. “Launching Vonage Silent Authentication API for the U.S. customers marks a tra
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 08:30:00 EET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 08:00:00 EET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations. “With ten posters spanning all key aesthetic treatment modalities and areas across the face and body, our data at IMCAS truly showcases the breadth and versatility of our injectable aesthetics portfolio and how we continue to drive innovation with our trusted products. In tandem with our first-class Galderma Aesthetic Injector Network (GAIN) educational activities, conducted in partnership with renowned experts, we are equ
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLD Symposium™ 202622.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study with oral nizubaglustat for late-infantile/juvenile GM2 and Niemann-Pick Type C diseases (RAINBOW) on February 5, presenting preliminary clinical efficacy and safety data. The data underscore nizubaglustat’s potential as a therapeutic option, reinforcing Azafaros’ commitment to addressing critical unmet needs in lysosomal storage disorders. Nizubaglustat reinstates pro-neuronal transcriptional programs in human CLN3 retinal organoidson February 6 (Rapid Fire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom